Beyond Your CancerIsoray passionately designs and develops innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer.
Isoray Medical, Inc. is an innovative company that designs and develops state-of-the-art, personalized brachytherapy products that provide a more cost-effective cancer treatment. Isoray employs approximately 40 employees, dedicated to the introduction of a unique isotope for the treatment of both common and also difficult to treat cancers.
Based in Richland, in the shadow of the Hanford Nuclear Reservation, Isoray leveraged the expertise in the region to develop a proprietary process for manufacturing a sought after new medical isotope, Cesium 131 used in brachytherapy treatment of cancer. Brachytherapy is a technique that places radiation sources (“seeds’) as close as possible to the tumor site to destroy cancer cells.
Cesium 131 has unique characteristics that have evolved into an effective treatment for many types of cancer. Specifically, Cesium 131 is able to provide a highly targeted, fast-acting radiation treatment that is able to deliver its energy in a shorter time period than conventional external beam radiation therapy or other isotopes currently used in brachytherapy, which is not only more cost-effective but typically results in less treatment side-effects.
The initial application for Cesium 131 is for the treatment of localized prostate cancer. The fast-acting nature of the treatment allows men to quickly recover from short term side-effects from radiation and return to normal urinary, bowel and sexual function faster than with other brachytherapy isotopes. A growing body of literature supports faster recovery when Cesium 131 brachytherapy is utilized.
In addition to serving as a novel, more efficient alternative for prostate brachytherapy treatment, Cesium 131 is showing great promise in other applications that previously had limited treatment alternatives, including recurrent gynecological cancers, brain tumors, sarcomas and other aggressive and recurrent tumors. Leading medical centers, hospitals and clinics across the United States are now offering this breakthrough treatment for cancer patients.
The fast-acting nature of the Cesium 131 isotope is well-suited to provide additional targeted radiation at the time of surgery, allowing for the treatment of residual disease while limiting the dose to surrounding healthy tissues. In many cases, the radiation “boost” can be delivered before conventional external beam radiation could even be started — while still delivering higher therapeutic doses.
In the case of brain cancer treatment, Isoray has submitted a 510(k) application for a novel delivery system developed in conjunction with the Barrow Neurological Institute (Phoenix, AZ) and is also pursuing a unique code to provide reimbursement.
Another exciting new application is for the treatment of recurrent gynecological tumors. Physicians at the University of Kentucky are using Cesium 131 to treat women with a less invasive approach, which historically has required extensive, debilitating surgical procedures. Early results are promising.
Isoray Medical is the sole producer of Cesium-131 brachytherapy sources, which are expanding brachytherapy treatments for difficult to treat cancers. Isoray is dedicated to pioneering cost-effective solutions for life beyond a patient’s cancer.
Review our SEC Filings, Codes of Conduct, & Management Teams.
We are always looking for talented people to join our team.
Join Us at the Following Events
American Association of Neurological Surgeons
April 30 - May 2, 2018 New Orleans, LA
American Urologic Association Annual Meeting 2018
May 18-22, 2018 San Francisco, CA
Dr. Brian J. Moran, Medical Director for the Chicago Prostate Cancer Center, stresses the importance of customizing each and every patient’s cancer treatment. “This disease is a spectrum disease,” says Moran.
Dr. Brian Moran, Medical Director for the Chicago Prostate Center, discusses the value of low-dose rate brachytherapy and its disruptive innovation in the cancer treatment field at ABS 2018.
GammaTile Therapy is the Next Step in the Expansion of Cesium to Additional Markets RICHLAND, Wash., July 09, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope...
With the 2018 edition of the American Brachytherapy Annual Meeting in the books, it is fitting to take a few minutes and highlight our top ABS 2018 Insights. The clinical experience with Cesium-131 continues to build: Dr. Manuj Agarwal of the University of Maryland...
Prostate Cancer News Today: “Prostate Cancer Patients Treated with Radioactive Seeds Retain Urinary, Bowel Quality”
“Prostate cancer patients treated with Cesium-131 brachytherapy maintained their urinary- and bowel-related quality of life years afterward, according to a recent study.” The study, “Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131,” was...
We remain excited by the mounting evidence that certain types of recurrent cancerous brain tumors can be effectively treated with Cesium-131 brachytherapy, prolonging survival and improving quality of life at the same time. From Lisa Esposito and Kristine Crane in...
IsoRay Announces the First Disposable Delivery System for Custom Intra-operative Strands for Prostate Cancer Treatment
RICHLAND, Wash., May 11, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological...
IsoRay Announces Second Quarter Fiscal 2018 Revenue of $1.54 Million, 50% Second Quarter-Over-Second Quarter Increase
Fourth Consecutive Quarter of Year-Over-Year Revenue Increases RICHLAND, Wash., Feb. 08, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE American:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment...
Dr. Timothy Showalter, a radiation oncologist, led the study on why a potentially life-saving treatment for cervical cancer was being less utilized. (Photo by Josh Barney, UVA Health System) “The evidence is clear: Cervical cancer is best treated with brachytherapy, a...
Will 2017 be remembered as the beginning of a brachytherapy renaissance? While much remains to be done in clinician education and patient advocacy, newly published data and patient engagement were high points for the Isoray team. A trove of new evidence demonstrates...